As the outcome shows, no matter the expression of HER2 was positive or negative, the survival of gastric cancer patients with positive Gli1 expression is poorer than the patients with negative ones (P = 0.003, P = 0.045, Fig. 2C,D). This evidence concerns the gene ERBB2 and gastric cancer.